Japan approved NovoCure's Optune Pax in unresectable locally advanced pancreatic cancer, based on PANOVA-3's median overall survival benefit. It follows the February FDA approval, so the platform thes

What happened: Japan's Ministry of Health, Labour and Welfare approved Optune Pax, a portable Tumor Treating Fields device, for use with gemcitabine and nab-paclitaxel in adults with unresectable locally Why it matters: The approval extends TTFields into a new hard-to-treat solid tumor indication in Japan, following the U.S. green light, which may strengthen the case that TTFields can be replicated across geographies. The content says near-term focus remains on prescription growth, payer coverage in lung and brain cancers, and losses and reimbursement friction delaying profitability. Market: +1.0% by next close ($14.72 on Oct 12), +5.5% YTD

Japan's Ministry of Health, Labour and Welfare approved Optune Pax, a portable Tumor Treating Fields device, for use with gemcitabine and nab-paclitaxel in adults with unresectable locally

The approval extends TTFields into a new hard-to-treat solid tumor indication in Japan, following the U.S. green light, which may strengthen the case that TTFields can be replicated across geographies. The content says near-term focus remains on prescription growth, payer coverage in lung and brain cancers, and losses and reimbursement friction delaying profitability. Market: +1.0% by next close ($14.72 on Oct 12), +5.5% YTD